Literature DB >> 12534452

Impact of diabetes duration and cardiovascular risk factors on mortality in type 2 diabetes: the Hoorn Study.

A M W Spijkerman1, J M Dekker, G Nijpels, A Jager, P J Kostense, V W M van Hinsbergh, L M Bouter, R J Heine, C D A Stehouwer.   

Abstract

BACKGROUND: Several studies have reported differences in the mortality risk between diabetic subjects detected by screening and known diabetic patients. We studied mortality in relation to diabetes duration, and the contribution of other cardiovascular risk factors to the elevated risk.
MATERIALS AND METHODS: Participants were type 2 diabetic subjects (n = 174) of a population-based cohort study. Of these, 95 were diagnosed by screening. Known diabetic subjects were grouped into two categories of diabetes duration, with a median duration of 2.4 and 11.2 years, respectively. We assessed the contribution of classical cardiovascular risk factors (dyslipidaemia, hypertension, and prior myocardial infarction), and of new cardiovascular risk factors (microalbuminuria, von Willebrand factor, sVCAM-1 and C-reactive protein) to the mortality risk during nearly 10 years of follow up. Cox's proportional hazards model was used to study the association of diabetes duration and mortality.
RESULTS: The age- and sex-adjusted relative risks of mortality were 2.06 (95% C.I. 1.04-4.10) and 3.19 (1.64-6.20) for the patients with short- and long-term diabetes compared with the screening-detected diabetic subjects, respectively. Adjustment for cardiovascular risk factors resulted in a reduction of mortality risk in both groups: 1.13 (0.51-2.50) and 2.39 (1.18-4.83), respectively. Mortality risk significantly increased with increasing diabetes duration, even after multiple adjustment (P-value for trend ranged from < 0.001-0.018).
CONCLUSIONS: Mortality risk increased with increasing diabetes duration. In subjects with short diabetes duration the mortality risk could largely be attributed to other risk factors. In subjects with a longer diabetes duration, however, the elevated mortality risk was independent of these cardiovascular risk factors.

Entities:  

Mesh:

Year:  2002        PMID: 12534452     DOI: 10.1046/j.1365-2362.2002.01090.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  13 in total

1.  Duration of diabetes and risk of ischemic stroke: the Northern Manhattan Study.

Authors:  Chirantan Banerjee; Yeseon P Moon; Myunghee C Paik; Tatjana Rundek; Consuelo Mora-McLaughlin; Julio R Vieira; Ralph L Sacco; Mitchell S V Elkind
Journal:  Stroke       Date:  2012-03-01       Impact factor: 7.914

2.  Relationship of microparticles to progenitor cells as a measure of vascular health in a diabetic population.

Authors:  Anne M Curtis; Lifeng Zhang; Elizabeth Medenilla; Ming Gui; Patrick F Wilkinson; Erding Hu; Jay Giri; Vijay Doraiswamy; Sampath Gunda; Mark E Burgert; Jonni S Moore; Jay M Edelberg; Emile R Mohler
Journal:  Cytometry B Clin Cytom       Date:  2010-06-11       Impact factor: 3.058

3.  Metabolic effects of fluvastatin extended release 80 mg and atorvastatin 20 mg in patients with type 2 diabetes mellitus and low serum high-density lipoprotein cholesterol levels: a 4-month, prospective, open-label, randomized, blinded-end point (probe) trial.

Authors:  Maurizio Bevilacqua; Barbara Guazzini; Velella Righini; Massimo Barrella; Rosanna Toscano; Enrica Chebat
Journal:  Curr Ther Res Clin Exp       Date:  2004-07

4.  Use of the Burden of Diabetes Mellitus Score for Cardiovascular Disease Risk Assessment.

Authors:  Peter D Farjo; Nadia Barghouthi; Noor Chima; Anand Desai; Wei Fang; Jennifer Giordano; Christopher M Bianco
Journal:  Am J Cardiol       Date:  2020-04-04       Impact factor: 2.778

5.  Prevalence of diabetic retinopathy in screening-detected diabetes mellitus: results from the Gutenberg Health Study (GHS).

Authors:  Katharina A Ponto; Jochem Koenig; Tunde Peto; Julia Lamparter; Philipp Raum; Philipp S Wild; Karl J Lackner; Norbert Pfeiffer; Alireza Mirshahi
Journal:  Diabetologia       Date:  2016-06-17       Impact factor: 10.122

6.  Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial.

Authors:  Simon J Griffin; Knut Borch-Johnsen; Melanie J Davies; Kamlesh Khunti; Guy E H M Rutten; Annelli Sandbæk; Stephen J Sharp; Rebecca K Simmons; Maureen van den Donk; Nicholas J Wareham; Torsten Lauritzen
Journal:  Lancet       Date:  2011-06-24       Impact factor: 79.321

7.  The excess mortality risk of diabetes associated with functional decline in older adults: results from a 7-year follow-up of a nationwide cohort in Taiwan.

Authors:  Chia-Lin Li; Hsing-Yi Chang; Yea-Ing L Shyu
Journal:  BMC Public Health       Date:  2011-12-23       Impact factor: 3.295

8.  Screening for type 2 diabetes in a high-risk population: study design and feasibility of a population-based randomized controlled trial.

Authors:  Bart Klijs; Suzie J Otto; Robert J Heine; Yolanda van der Graaf; Jan J Lous; Harry J de Koning
Journal:  BMC Public Health       Date:  2012-08-17       Impact factor: 3.295

9.  Diabetes severity and the role of leisure time physical exercise on cardiovascular mortality: the Nord-Trøndelag Health study (HUNT), Norway.

Authors:  Børge Moe; Liv Berit Augestad; Tom I L Nilsen
Journal:  Cardiovasc Diabetol       Date:  2013-06-06       Impact factor: 9.951

10.  Joint predictability of health related quality of life and leisure time physical activity on mortality risk in people with diabetes.

Authors:  Chia-Lin Li; Hsing-Yi Chang; Chih-Cheng Hsu; Jui-fen Rachel Lu; Hsin-Ling Fang
Journal:  BMC Public Health       Date:  2013-01-24       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.